Valuation
- Market cap
- 746,708,000
- Revenue TTM
- $376,130,000
- Net income TTM
- $2,850,000
- PE ratio
- 89.83
- Forward PE
- 34.46
- Profit margin
- 0.76%
- Debt to equity
- 0.02
Trading
- Volume
- 29,000
- Avg volume
- 23,810
- Day's range
- $11.85 – $12.28
- Shares out
- 70,778,000
- Stochastic %K
- 99%
- Beta
- 0.01
- Analysts
- Strong Sell
- Price target
- $38.00
Company profile
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniol...
Show more
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 31 71 524 7400
- Website
- https://www.pharming.com
- Address
- Darwinweg 24, Leiden, Netherlands
Latest news
No headlines yet.
